85.15 USD
+0.11 (+0.13%)
We assign a fundamental rating of 7 out of 10 to LMAT. LMAT was compared to 185 industry peers in the Health Care Equipment & Supplies industry. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. LMAT has a correct valuation and a medium growth rate. These ratings could make LMAT a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year LMAT was profitable.
In the past year LMAT had a positive cash flow from operations.
LMAT had positive earnings in each of the past 5 years.
LMAT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
LMAT has a better Return On Assets (8.92%) than 91.35% of its industry peers.
The Return On Equity of LMAT (14.08%) is better than 90.27% of its industry peers.
LMAT has a Return On Invested Capital of 8.43%. This is amongst the best in the industry. LMAT outperforms 87.03% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 8.84%.
The 3 year average ROIC (8.26%) for LMAT is below the current ROIC(8.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROIC | 8.43% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
Looking at the Profit Margin, with a value of 22.14%, LMAT belongs to the top of the industry, outperforming 94.05% of the companies in the same industry.
LMAT's Profit Margin has improved in the last couple of years.
LMAT's Operating Margin of 25.71% is amongst the best of the industry. LMAT outperforms 95.14% of its industry peers.
LMAT's Operating Margin has improved in the last couple of years.
LMAT's Gross Margin of 70.97% is fine compared to the rest of the industry. LMAT outperforms 79.46% of its industry peers.
LMAT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
LMAT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LMAT has more shares outstanding
The debt/assets ratio for LMAT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.27 indicates that LMAT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.27, LMAT belongs to the top of the industry, outperforming 84.86% of the companies in the same industry.
The Debt to FCF ratio of LMAT is 2.54, which is a good value as it means it would take LMAT, 2.54 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.54, LMAT belongs to the top of the industry, outperforming 84.86% of the companies in the same industry.
LMAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
LMAT has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Altman-Z | 7.27 |
ROIC/WACC0.87
WACC9.73%
2.3 Liquidity
LMAT has a Current Ratio of 13.58. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.58, LMAT belongs to the best of the industry, outperforming 97.84% of the companies in the same industry.
A Quick Ratio of 11.45 indicates that LMAT has no problem at all paying its short term obligations.
LMAT has a Quick ratio of 11.45. This is amongst the best in the industry. LMAT outperforms 95.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.67% over the past year.
LMAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.13% yearly.
Looking at the last year, LMAT shows a quite strong growth in Revenue. The Revenue has grown by 13.07% in the last year.
Measured over the past years, LMAT shows a quite strong growth in Revenue. The Revenue has been growing by 13.41% on average per year.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
3.2 Future
The Earnings Per Share is expected to grow by 11.10% on average over the next years. This is quite good.
Based on estimates for the next years, LMAT will show a quite strong growth in Revenue. The Revenue will grow by 9.65% on average per year.
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 38.88, the valuation of LMAT can be described as expensive.
LMAT's Price/Earnings ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 71.35% of the companies in the same industry.
LMAT is valuated rather expensively when we compare the Price/Earnings ratio to 27.00, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 32.27, which means the current valuation is very expensive for LMAT.
Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than the industry average as 72.43% of the companies are valued more expensively.
LMAT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.88 | ||
| Fwd PE | 32.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, LMAT is valued a bit cheaper than the industry average as 77.30% of the companies are valued more expensively.
81.08% of the companies in the same industry are more expensive than LMAT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.17 | ||
| EV/EBITDA | 19.9 |
4.3 Compensation for Growth
LMAT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
LMAT's earnings are expected to grow with 14.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.41
PEG (5Y)2.27
EPS Next 2Y16.63%
EPS Next 3Y14.06%
5. Dividend
5.1 Amount
LMAT has a yearly dividend return of 0.99%, which is pretty low.
Compared to an average industry Dividend Yield of 0.20, LMAT pays a better dividend. On top of this LMAT pays more dividend than 91.89% of the companies listed in the same industry.
With a Dividend Yield of 0.99, LMAT pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.99% |
5.2 History
The dividend of LMAT is nicely growing with an annual growth rate of 13.60%!
LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
LMAT pays out 32.20% of its income as dividend. This is a sustainable payout ratio.
The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
NASDAQ:LMAT (1/9/2026, 1:38:03 PM)
85.15
+0.11 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.2%
Inst Owner Change0%
Ins Owners7.98%
Ins Owner Change-4.67%
Market Cap1.93B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.82
Price Target105.74 (24.18%)
Short Float %5.41%
Short Ratio6.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.99% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.64%
PT rev (3m)-1.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.07%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)6.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.88 | ||
| Fwd PE | 32.27 | ||
| P/S | 8.02 | ||
| P/FCF | 29.17 | ||
| P/OCF | 26.37 | ||
| P/B | 5.1 | ||
| P/tB | 6.87 | ||
| EV/EBITDA | 19.9 |
EPS(TTM)2.19
EY2.57%
EPS(NY)2.64
Fwd EY3.1%
FCF(TTM)2.92
FCFY3.43%
OCF(TTM)3.23
OCFY3.79%
SpS10.62
BVpS16.7
TBVpS12.4
PEG (NY)1.41
PEG (5Y)2.27
Graham Number28.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROCE | 10.97% | ||
| ROIC | 8.43% | ||
| ROICexc | 21.47% | ||
| ROICexgc | 38.36% | ||
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% | ||
| FCFM | 27.5% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 68.51% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.46% | ||
| Profit Quality | 124.17% | ||
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 | ||
| Altman-Z | 7.27 |
F-Score5
WACC9.73%
ROIC/WACC0.87
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year45.26%
EBIT Next 3Y22.27%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%
LEMAITRE VASCULAR INC / LMAT FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a valuation rating of 5 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 38.88 and the Price/Book (PB) ratio is 5.1.
How financially healthy is LEMAITRE VASCULAR INC?
The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 7 / 10.